On May 27, 2021 "In China, the biopharma industry has been entering a period of incredibly rapid development," says Dr. PC Zhu, Founder and CEO of ATLATL, the leading Innovation Center in Shanghai (Press release, Mabwell Biotech, MAY 27, 2021, View Source [SID1234580715]). "Scores of companies with rich pipelines and robust capabilities have listed or filed listing applications in the past few years, and the portfolio companies at our campus have raised tremendous funds, just like my previous incubator in Boston." Mabwell, a typical case of such a start-up company, reported that has raised $279 million (RMB ¥1.97 billion) from a series of investors, ranking in the Top 5 Venture Raises of 2020, and is currently preparing for listing on SSE STAR market.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mabwell is representative of the success of Chinese biopharma start-ups, ranking 5th on the list of the Top 10 money raisers of 2020 around the world, as ranked by Fiercebiotech (released in Mar. 2021) and 2nd in the list of the Top 20 Venture Raises of 2020 in ex-US regions, as listed in LavoieHealthScience (released in Oct. 2020). Founded in 2017, Mabwell focuses on the discovery, development, manufacture, and commercialization of innovative biologics and has set-up 9 subsidiaries to accelerate the industrialization process. Currently, Mabwell has a pipeline of 15 biologics in the areas of immunology, oncology, metabolic diseases, ophthalmology, and infectious diseases, and 8 products in the clinical stage are expected to be commercialized by 2023-2026. The first product, Adalimumab biosimilar, is expected to be marketed in 2021. Earlier this year, Mabwell obtained the IND acceptance for an anti-ST2 monoclonal antibody, making it the first Chinese company to apply this target IND submission and receive acceptance.

For venture capital, pipeline and capability may be the most immediate concerns. A high value pipeline means a promising future and generous returns. In addition, a company with comprehensive capabilities guarantees smooth sailing in every process, especially clinical development, which is significant in the fierce, competitive field of drug development. With expansion of the local market and investment, and growing support from the Chinese government, an increasing number of biopharma start-ups in China are expected to raise more money to strengthen pipelines and improve capabilities. With this trend, it is easily foreseeable that Chinese biopharma companies will be even more competitive in the global market in the next decade.

On May 27, 2021 Photocure ASA (OSE: PHO), The Bladder Cancer Company, reported that President and Chief Executive Officer, Daniel Schneider and Chief Financial Officer, Erik Dahl are scheduled to present corporate overviews at two upcoming institutional investor conferences in June (Press release, PhotoCure, MAY 27, 2021, View Source [SID1234583248]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the two presentations are as follows:

The MicroCap Rodeo 2021 Summer Solstice – Best Ideas from the Buyside: June 1-4, 2021. Photocure will present on Tuesday June 1 at 3:00pm CET / 9:00am ET. Management will be available for virtual 1-1 meetings with investors attending the virtual conference.
Access to the live event/webcast is available by clicking here: www.webcaster4.com/Webcast/Page/2134/41489

The MicroCap Rodeo’s third edition is a virtual conference this year focused on investors in the United States. It brings together the top 35 "best ideas from the buy side". Qualified institutional investors recommended each of the 35 companies represented as one of their "best ideas". For more information: microcaprodeo.com.

Handelsbanken Nordic Mid/Small Cap Seminar 2021: June 2-3, 2021. Photocure will present on Wednesday, June 2 at 4:15pm CET / 10:15am ET. Management will be available for virtual 1-1 meetings with investors.
Handelsbanken Capital Markets’ 12th consecutive Nordic Mid/Small Cap Seminar is a two-day intensive event featuring senior leadership speakers from an array of Nordic Mid/Small Cap companies. All presentations will be digital and presenting companies will host meetings with institutional investors signed up for the conference.

On May 27, 2021 Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, reported that management will be presenting at the Jefferies Healthcare Conference on Thursday, June 3, 2021 at 3:00 p.m. ET (Press release, Tempest Therapeutics, MAY 27, 2021, View Source [SID1234585164]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the archived recording of the company presentation, please visit the Tempest website at www.tempesttx.com.

On May 27, 2021 CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, reported that CorMedix management will present a corporate overview at the Jefferies Virtual Healthcare Conference taking place on June 1 – 4, 2021 (Press release, CorMedix, MAY 27, 2021, View Source [SID1234580683]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference
Date: Friday, June 4
Time: 11:30 am Eastern Time
Webcast: View Source

On May 27, 2021 OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) and the FoRT Foundation (Fondazione Ricerca Traslazionale) reported that the Italian Medicines Agency (AIFA) and the Italian Ethics Committee approved the initiation of a new Phase 2 clinical trial evaluating Tedopi in combination with Opdivo or chemotherapy as second-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) (Press release, OSE Immunotherapeutics, MAY 27, 2021, View Source [SID1234580716]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This three-arm Phase 2 study will evaluate neo-epitope-based vaccine Tedopi in combination with Bristol Myers Squibb’s Opdivo (nivolumab), an immune checkpoint inhibitor, or Tedopi plus chemotherapy or chemotherapy alone as second-line treatment in HLA-A2 positive patients with metastatic NSCLC after first-line chemo-immunotherapy.

The clinical trial will be sponsored by the Italian oncology Foundation FoRT. It will be supported by Bristol Myers Squibb, which will provide Opdivo, and by OSE Immunotherapeutics, which will provide Tedopi for the study as well as a partial financial support.

Federico Cappuzzo, M.D., Ph.D., Director Medical Oncology at Cancer Institute Regina Elena, Roma, Italy, and Chief Investigator of the study, comments: "Checkpoint inhibitors are now often used in first-line settings in combination with chemotherapy. For patients who have disease progression after checkpoint inhibitors, the standard second-line option remains chemotherapy. In particular for NSCLC patients with disease progression, we need additional second-line combinations of immuno-therapeutic agents to provide these patients with new options. The trial will evaluate a new treatment strategy with the combination of therapeutic vaccine Tedopi which, by activating T lymphocytes, might efficiently optimize a checkpoint inhibitor or chemotherapy treatment."

Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, comments: "We are very pleased to collaborate with Dr Federico Cappuzzo and FoRT to evaluate Tedopi in combination with Opdivo in second-line treatment of NSCLC patients after chemo-immunotherapy. This additional development program of Tedopi in NSCLC will expand the product’s clinical data in this indication for a patient population who needs innovative treatment options. Tedopi was evaluated as monotherapy post-checkpoint failure in NSCLC and already demonstrated positive results for the Step-1 of its Phase 3 Atalante trial, as presented at the 2020 ESMO (Free ESMO Whitepaper) congress*."

* OSE Immunotherapeutics presented positive results of Step-1 of its Phase 3 Atalante 1 clinical trial, including a significant increase in overall survival in NSCLC patients after failure with checkpoint inhibitor (survival rate at 12 months in the patients treated with Tedopi versus standard of care). Today, OSE Immunotherapeutics intends to discuss with the regulatory health authorities, the U.S. Food and Drug Administration and the European Medicines Agency, to determine the best options to continue development of Tedopi and to maximize the data obtained in terms of risk / benefit ratio